FIGURE 1.
Schema of study A26. aProportion of scans with τAD+ (∼5%) and τAD++ (∼95%) reflected prevalence in TB2 study. bScans that were negative or had failed FTP quantitation were not used for calculating endpoints. cParticipants with negative scans were identified from screen-failed subjects to TB2 study.
